Clinical Trial Update: Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating safety and efficacy of alpha1-proteinase inhibitor in HIV disease; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Disease

Drugs mentioned

• Alpha1 proteinase inhibitor (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Institute for Human Genetics and Biochemistry | Conditions: HIV Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2020-08-31